Agios (AGIO) Q2 Revenue Jumps 45%
Agios Pharmaceuticals (NASDAQ:AGIO), a biotechnology company focused on therapies for rare blood disorders, released its second quarter 2025 earnings on July 31, 2025. The headline was a notable revenue beat: This quarter showcased clear progress on sales for its lead product PYRUKYND, with GAAP net product revenue of $12.5 million, yet also highlighted the company's increasing cost base as it prepares for major regulatory events and launches. Overall, the quarter delivered strong revenue momentum, but at the expense of deeper losses as Agios prepares for its next wave of product launches.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Agios Pharmaceuticals specializes in discovering and commercializing drugs for rare blood diseases. The company primarily focuses on conditions with high unmet needs, allowing it to address specialized patient populations. Its flagship product, PYRUKYND, is an oral medication that targets pyruvate kinase deficiency, a rare genetic disorder causing anemia. The company’s core strategy centers on expanding the reach of PYRUKYND to other rare diseases, notably thalassemia and sickle cell disease, through further clinical trials and regulatory filings.
Source Fool.com
Agios Pharmaceuticals Inc. Aktie
Einige Buy-Einschätzungen geben Agios Pharmaceuticals Inc. den Vorteil gegenüber Sell-Einschätzungen.
Die Community erwartet für Agios Pharmaceuticals Inc. ein Kursziel von 42 €, was eine deutliche Steigerung von über 50% gegenüber dem aktuellen Kurs von 21.4 € bedeuten könnte.
